Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

S Hendry; DJ Byrne; GM Wright; RJ Young; S Sturrock; WA Cooper; SB Fox

Journal article

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

S Hendry, DJ Byrne, GM Wright, RJ Young, S Sturrock, WA Cooper, SB Fox

Journal of Thoracic Oncology | ELSEVIER SCIENCE INC | Published : 2018

DOI: 10.1016/j.jtho.2017.11.112

Abstract

Introduction: Four different programmed death ligand 1 immunohistochemical assays are approved or in development as companion or complementary diagnostics to different immunotherapeutic agents in lung carcinoma. We sought to determine whether these assays are technically equivalent and whether one antibody can be used on an alternate staining platform. Methods: Serial sections of tissue microarrays constructed from 368 cases of resected lung cancer were stained for 22C3 and 28-8 on the Dako Link 48 platform (Dako, Carpinteria, Ca) and for SP142 and SP263 on the Ventana Benchmark Ultra platform (Ventana Medical Systems, Tucson, AZ) strictly as per product insert. A protocol was developed to u..

View full abstract

University of Melbourne Researchers

Gavin Wright Author

Stephen Fox Author

Related Projects (1)

TRANSLATING MOLECULAR PATHOLOGY INTO CANCER DIAGNOSTICS

The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and techn..

Grants

Funding Acknowledgements

Dr. Fox is supported by an NHMRC Practitioner Fellowship. The authors would like to thank Prudence A. Russell for provision of tissue samples and histological subtype information, as well as Roche Diagnostics Australia for provision of the SP263 and SP142 assay kits, Merck and Co. for the 22C3 assay kit, and Bristol Myers Squibb for the 28-8 assay kit.